The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-16 and is reviewed periodically as new material appears.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Studies show that Safe Routes to School programs are effective at increasing rates of bicycling and walking to school and decreasing injuries (Safe Routes Partnership). According to authors from the state of childhood obesity, their focus was on a few programs and policies regarding children. The Child and Adult Food Care Program (CACFP) provides federal funding to many states to reimburse providers for the cost of providing healthy meals to children and adults in their care. Around 4.3 million children and 130,000 adults partake in this program each year. Providers are required to meet the minimum nutrition standards to receive reimbursement. Some of their nutrition requirements are more whole grains, a wider variety of fruits and vegetables, free added sugars, and less saturated fat. The goal is to increase children's intake of these healthy foods, reduce their consumption of grain-based desserts, and improve their overall health. Research has been done on this program and it has been found that participation in CACFP moderately increases the consumption of milk and vegetables among children, and it helps regulate their weight. Another early childhood education program that helps prepare children for school by providing education, health, and social services is Head Start. This program reaches over one million children who have family economic trouble each year. Early Head Start serves children aged three and under and pregnant women. Head Start and Early Head Start programs participate in either CATFP or the federal school meals programs.
For women, the Population Reference Intake is 13 mg/day for ages 15–17 years, 16 mg/day for women ages 18 and up who are premenopausal, and 11 mg/day postmenopausal; for pregnancy and lactation, 16 mg/day. For men, the Population Reference Intake is 11 mg/day for ages 15 and older. For children ages 1 to 14, the Population Reference Intake increases from 7 to 11 mg/day. The Population Reference Intakes are higher than the US RDAs, with the exception of pregnancy.
The Soviet military maintained control over the space program; Korolev's OKB-1 design bureau was subordinated under the Ministry of General Machine Building, tasked with the development of intercontinental ballistic missiles, and continued to give its assets random identifiers into the 1960s. Information about failures was systematically withheld, historian James Andrews notes that Soviet media coverage of the space program, particularly human space missions, rarely reported any failures or difficulties, creating the impression of a flawless operation:"With almost no exceptions, coverage of Soviet space exploits, especially in the case of human space missions, omitted reports of failure or trouble".Dominic Phelan noted in the book Cold War Space Sleuths (Springer-Praxis 2013): "The USSR was famously described by Winston Churchill as 'a riddle, wrapped in a mystery, inside an enigma' and nothing signified this more than the search for the truth behind its space program during the Cold War. Although the Space Race was literally played out above our heads, it was often obscured by a figurative 'space curtain' that took much effort to see through".
However, after the East Pakistani Awami League emerged victorious over the Pakistan Peoples Party (PPP), Yahya Khan and the military refused to transfer power. This led to Operation Searchlight, a military crackdown, and eventually sparked the war of liberation by Bengali Mukti Bahini forces in East Pakistan, described in West Pakistan as a civil war rather than a liberation struggle.
== Analysis == Some analysts have identified this operation as a hybridization of the war on terror and the war on drugs. According to Pino Arlacchi, the former head of the UN Office on Drugs and Crime, the portrayal of Venezuela as a "drug state" is a "geopolitically motivated smear campaign" by the US government; he refers to the World Drug Report 2025 and his own experience, according to which the Venezuelan government's cooperation in the fight against drug trafficking is among the best in South America. According to Arlacchi, the US has taken an interest in Venezuelan oil reserves, which are among the largest in the world. An article published in December 2025 by the Council on Foreign Relations stated that some experts believe that the "scope and intensity" of the Operation indicate that the Trump administrations's goals extend beyond combatting drug trafficking to a "broader plan to oust Maduro". An analysis by the Costs of War Project estimated that Operation Southern Spear and Operation Absolute Resolve, from August 1, 2025 to March 31, 2026, cost at least $4.7 billion in government funds.
Sources: en.wikipedia.org
=== Acquired resistance === Evolution of microbial resistance to vancomycin is a growing problem, especially in healthcare facilities such as hospitals. While newer alternatives to vancomycin exist, such as linezolid (2000) and daptomycin (2003), the widespread use of vancomycin makes resistance to it a significant worry, especially for individual patients if resistant infections are not quickly identified and the patient continues an ineffective treatment. Vancomycin-resistant Enterococcus emerged in 1986. Vancomycin resistance evolved in more common pathogenic organisms during the 1990s and 2000s, including vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA). Agricultural use of avoparcin, another similar glycopeptide antibiotic, may have contributed to the evolution of vancomycin-resistant organisms. One mechanism of resistance to vancomycin involves the alteration to the terminal amino acid residues of the NAM/NAG-peptide subunits, under normal conditions, D-alanyl-D-alanine, to which vancomycin binds. The D-alanyl-D-lactate variation results in the loss of one hydrogen-bonding interaction (4, as opposed to 5 for D-alanyl-D-alanine) possible between vancomycin and the peptide. This loss of just one point of interaction results in a 1000-fold decrease in affinity. The D-alanyl-D-serine variation causes a six-fold loss of affinity between vancomycin and the peptide, likely due to steric hindrance. In enterococci, this modification appears to be due to the expression of an enzyme that alters the terminal residue.
In their 8 June 2017 press release they also noted that, this was the first time the FDA had taken steps to "remove a currently marketed opioid pain medication from sale due to public health consequences of abuse." By 6 July 2017, Endo International voluntarily complied with the FDA removal request.
HIV infection In October 2016, scientists from Emory University and National Institute of Allergy and Infectious Diseases (NIAID) published a paper which claimed that they applied daily ART (antiretroviral therapy) of 90 days followed by simianized (rhesus macaques) anti α4β7 antibody on SIV+ rhesus macaques for 23 weeks. Twenty three months after stopping both ART and anti-α4β7 antibody treatment, the in vivo SIV level still remained undetectable. Therefore, treating HIV+ people with ART and anti-α4β7 simultaneously may be a new therapy that could potentially lead to an HIV infection cure. In mice, vedolizumab was not able to prevent or control HIV-infections. Phase 1 clinical trial of that therapy has been initialized by NIAID since May 2016. For each of the participants, they will get vedolizumab infusions every four weeks for 30 weeks. Before the 23rd week of vedolizumab infusions, cART (combination ART) is kept. During the 30 weeks, blood draws are repeated for baseline tests. After the 22-week-cART is stopped, both viral load and CD4 count will be monitored biweekly. If HIV viral load goes high or their CD4 cell counts decrease by too much when vedolizumab is used alone, cART will be brought back on the participants. The published results from this clinical trial suggest "that blockade of α4β7 may not be an effective strategy for inducing virological remission in HIV-infected individuals after ART interruption" because only one patient showed prolonged virus suppression.
==== Academic licencing, licence steering and AI commercialisation ==== The use of academic research for Large Language Models (LLMs) has sparked debate within the Open Access movement. Academics accuse publishers of steering authors towards restrictive licences to retain exclusive commercial rights for AI training deals. In 2024, publishers like Taylor & Francis announced lucrative AI training partnerships, often without consulting authors. This dynamic complicates copyright litigation, as seen in the US when Elsevier sued Meta over Llama AI models, acting as the class representative due to exclusive commercial rights granted by authors.
Like all members of the Loxosceles genus, the brown recluse has potent tissue-destroying venoms containing the dermonecrotic agent sphingomyelinase D. Most bites are minor with no dermonecrosis, but a small number of brown recluse bites produce loxoscelism, a condition where the skin around the bite dies. While loxoscelism usually manifests as a skin condition (cutaneous loxoscelism), it can also include systemic symptoms like fever, nausea, and vomiting (viscerocutaneous loxoscelism). In very rare cases, bites can even cause hemolysis – the bursting of red blood cells. In one study of clinically diagnosed brown recluse bites, skin necrosis occurred 37% of the time, while systemic illness occurred 14% of the time. As suggested by its specific name reclusa (recluse), the brown recluse spider is rarely aggressive, and bites from the species are uncommon. In 2001, more than 2,000 brown recluse spiders were removed from a heavily infested home in Kansas, yet the four residents who had lived there for years were never harmed by the spiders, despite many encounters with them. The spider usually bites only when pressed against the skin, such as when tangled within clothes, shoes, towels, bedding, or inside work gloves. Many human victims report having been bitten after putting on clothes or shoes that had not been worn recently or had been left for many days undisturbed on the floor. The fangs of the brown recluse are not large enough to penetrate most fabric.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.